Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413542 · ClinicalTrials.gov registry record · NA
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01413542 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 44 participants.
The verdict
NCT01413542, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
Interventions
- DRUG Sitagliptin (DPP4 inhibitor)
- DRUG Substance P,
- DRUG bradykinin
- DRUG enalaprilat (ACE inhibitor)
- DRUG Glucagon-like peptide 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01413542
The ClinicalTrials.gov registry entry for NCT01413542 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sitagliptin (DPP4 inhibitor) is the first listed.
NCT01413542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01413542 about?
NCT01413542 is a clinical study titled "Pharmacogenetics of Ace Inhibitor-Associated Angioedema". The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these d...
What is the current status of trial NCT01413542?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2011-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01413542?
The interventions under investigation include: Sitagliptin (DPP4 inhibitor) (DRUG), Substance P, (DRUG), bradykinin (DRUG), enalaprilat (ACE inhibitor) (DRUG), Glucagon-like peptide 1 (DRUG).
Who is sponsoring clinical trial NCT01413542?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.